(Crotedumab)Biosimilar Reference Antibody-GS40155 新品

货号：GS40155

Crotedumab (REGN1193) is an investigational humanized IgG4 monoclonal antibody developed as a glucagon receptor antagonist. It is designed to specifically bind to and inhibit the activity of the glucagon receptor, a key regulator of glucose metabolism. This mechanism of action positions it as a potential novel therapy for metabolic disorders, most notably type 2 diabetes mellitus, where excessive glucagon signaling contributes to hyperglycemia. By modulating this pathway, it aims to lower blood glucose levels through a mechanism distinct from current insulin-centric or incretin-based therapies.